<?xml version="1.0" encoding="UTF-8"?>
<study api_version="0.6">
  <id>1679</id>
  <name>UK10K_NEURO_UKSCZ</name>
  <active>true</active>
  <user_id>82</user_id>
  <followers>
    <follower>
      <login>elg</login>
      <email>elg@sanger.ac.uk</email>
      <name>Emma Gray</name>
      <id>236</id>
    </follower>
    <follower>
      <login>cj5</login>
      <email>cj5@sanger.ac.uk</email>
      <name>Chris Joyce</name>
      <id>305</id>
    </follower>
  </followers>
  <managers>
    <manager>
      <login>jws</login>
      <email>jws@sanger.ac.uk</email>
      <name>James Stalker</name>
      <id>82</id>
    </manager>
    <manager>
      <login>sm15</login>
      <email>sm15@sanger.ac.uk</email>
      <name>Shane McCarthy</name>
      <id>618</id>
    </manager>
  </managers>
  <owners>
    <owner>
      <login>jws</login>
      <email>jws@sanger.ac.uk</email>
      <name>James Stalker</name>
      <id>82</id>
    </owner>
    <owner>
      <login>sm15</login>
      <email>sm15@sanger.ac.uk</email>
      <name>Shane McCarthy</name>
      <id>618</id>
    </owner>
  </owners>
  <!-- Family has been deprecated -->
  <family_id></family_id>
  <created_at>2010-11-18 11:24:33 +0000</created_at>
  <updated_at>2013-04-05 12:19:51 +0100</updated_at>
  <descriptors>
    <descriptor>
      <name>Study description</name>
      <value>	In the UK10K project we propose a series of complementary genetic approaches to find new low frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will analyse directly quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches. 

The UK schizophrenia samples will be part of the neurodevelopmental disease group, and will undergo exome sequencing. </value>
    </descriptor>
    <descriptor>
      <name>Does this study contain samples that are contaminated with human DNA which must be removed prior to analysis?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Does this study require the removal of X chromosome and autosome sequence?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Does this study require y chromosome data to be separated from x and autosomal data before archival?</name>
      <value>false</value>
    </descriptor>
    <descriptor>
      <name>ENA Project ID</name>
      <value>0</value>
    </descriptor>
    <descriptor>
      <name>Abstract</name>
      <value>The samples from patients with schizophrenia have been collected
systematically across community mental health teams and clinics in South
Wales. All samples are from UK Caucasian participants. The
UK10K_NEURO_UKSCZ sample set also includes samples from participant's
relatives (without schizophrenia/psychosis).</value>
    </descriptor>
    <descriptor>
      <name>Title</name>
      <value>UK10K exome sequence: UK schizophrenia samples</value>
    </descriptor>
    <descriptor>
      <name>ENA Study Accession Number</name>
      <value>EGAS00001000123</value>
    </descriptor>
    <descriptor>
      <name>Study Visibility</name>
      <value>Hold</value>
    </descriptor>
    <descriptor>
      <name>Do any of the samples in this study contain human DNA?</name>
      <value>Yes</value>
    </descriptor>
    <descriptor>
      <name>Are all the samples to be used in this study commercially available, unlinked anonymised cell-lines?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Study name abbreviation</name>
      <value>UK10K_UKSCZ</value>
    </descriptor>
    <descriptor>
      <name>What is the data release strategy for this study?</name>
      <value>managed</value>
    </descriptor>
    <descriptor>
      <name>Will you be using WTSI's standard access agreement?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>How is the data release to be timed?</name>
      <value>standard</value>
    </descriptor>
    <descriptor>
      <name>Reason for delaying release</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Delay for</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Alignments in BAM</name>
      <value>true</value>
    </descriptor>
    <descriptor>
      <name>Please explain the reason for delaying release</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding data release timing and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Policy Url</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Policy title</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>EGA DAC Accession Number</name>
      <value>EGAC00001000024</value>
    </descriptor>
    <descriptor>
      <name>EGA Policy Accession Number</name>
      <value>EGAP00001000021</value>
    </descriptor>
    <descriptor>
      <name>ArrayExpress Accession Number</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Has the delay period been approved by the data sharing committee for this project?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>What is the reason for preventing data release?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Has this been approved?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding prevention of data release and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Data access group</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>SNP study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>SNP parent study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Number of gigabases per sample (minimum 0.15)</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>HMDMC approval number</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Study Type</name>
      <value>Exome Sequencing</value>
    </descriptor>
    <descriptor>
      <name>What sort of study is this?</name>
      <value>genomic sequencing</value>
    </descriptor>
    <descriptor>
      <name>Reference Genome</name>
      <value>Homo_sapiens (1000Genomes)</value>
    </descriptor>
    <descriptor>
      <name>Faculty Sponsor</name>
      <value>Richard Durbin</value>
    </descriptor>
  </descriptors>
</study>
